Go to Homepage
  • About
    • Mission and values
    • Leadership team
    • Careers
    • atai impact
  • Programs
    • Pipeline
    • Therapeutic areas
    • Clinical trials
    • Scientific publications
  • Investors
        • News, events & presentations
          • Press releases
          • Events
          • Presentations
        • Stock information
          • Stock quote & chart
          • Analyst coverage
        • Corporate governance
          • Governance overview
          • Management & supervisory board
          • Committee composition
        • SEC filings
          • SEC filings
          • Annual reports
        • Shareholder services
          • Investor FAQs
          • Email alerts
          • Contact IR
  • News
    • Thought leadership
    • Press releases
    • Media
  • Contact us
Media

FDA rejected MDMA-assisted PTSD therapy. Other psychedelics firms intend to avoid that fate

science logo
View external article

Download our
corporate presentation

atai presentation
an icon of a newsletter

Click here to join
the atai newsletter

Go to Homepage
  • Careers
  • Privacy Statement
  • Cookie policy

© 2025 Atai Life Sciences N.V., All Rights Reserved

You are now leaving atai Life Sciences’ website and entering a site that is not owned or controlled by atai.

atai makes no representations regarding the accuracy of the information on external websites and does not endorse their content. Your use of third-party websites is at your own risk and subject to their terms and conditions.